Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics

Aeglea BioTherapeutics

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics Inc

WIIM

ALLT

Allot shares are trading higher after the company announced it secured a multi-million dollar deal to boost cybersecurity for a tier 1 EMEA telecom operator.

The United States is bracing for a potential acceleration in inflation, with a significant depreciation of the dollar now identified as a key contributing factor, according to a new analysis by Torsten Sløk, the chief economist at Apollo.
What Happened: As per Sløk&#8217;s <a href="https://www.apolloacademy.com/the-10-depreciation-in-the-dollar-will-boost-inflation-by-0-3-percentage-points/">analysis</a>, a 10% depreciation in the U.S. dollar is projected to boost inflation by 0.3 percentage points.
This comes at a time when inflationary pressures are already building from multiple fronts, including ongoing tariffs, rising oil prices, and existing immigration restrictions.
Sløk emphasizes that &#8220;The bottom line is that we should see inflation move higher over the coming months; that is what the consensus expects, what the Fed expects, and what we expect.&#8221;
As the U.S. Dollar Index Spot has already declined by 10.29% on a year-to-date basis, a chart tracking the &#8220;Shock to Inflation, compared with consensus forecast&#8221; illustrates the projected impact.
A 10% depreciation occurring in the first half of a year (H1) shows a noticeable upward bump to inflation, as does a 10% depreciation in the second half (H2).
The chart also details the impact on U.S. CPI from both a 10% and a 20% depreciation in the dollar, relative to baseline forecasts, stretching from the first quarter of 2025 through the fourth quarter of 2027.
<figure class="wp-block-image size-large"><a href="https://www.apolloacademy.com/the-10-depreciation-in-the-dollar-will-boost-inflation-by-0-3-percentage-points/"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-1024x563.png" alt="" class="wp-image-974689" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart.png 1435w" sizes="(max-width: 1024px) 100vw, 1024px" /></a><figcaption class="wp-element-caption">Source: Apollo Academy</figcaption></figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46269226/stocks-just-hit-rare-golden-cross-for-1st-time-since-2023-heres-what-it-means-for-investors">Stocks Just Hit Rare Golden Cross For 1st Time Since 2023 — Here&#8217;s What It Means For Investors</a>
Why It Matters: During a discussion with Blomberg Television, Sløk was asked about the business environment being stronger than consensus expectations in terms of hiring, without the inflationary impulse.
He said, &#8220;That brings us back to a discussion around what are the effects of the trade war? Are tariffs not going to have an impact? So far, it&#8217;s remarkable, where you have inflation still steady, and now the job growth still strong. So in that sense, there is literally very little sign of the trade war having a macroeconomic impact at this point.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Torsten Slok, chief economist at Apollo, reacts to the June US jobs report, which saw the unemployment rate move down to 4.1% with job growth that exceeded expectations for a fourth straight month <a href="https://t.co/ucnIBVQGMM">https://t.co/ucnIBVQGMM</a> <a href="https://t.co/VOhBqK7ZQY">pic.twitter.com/VOhBqK7ZQY</a>
&mdash; Bloomberg TV (@BloombergTV) <a href="https://twitter.com/BloombergTV/status/1940780912268001439?ref_src=twsrc%5Etfw">July 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The U.S. Dollar Index Spot was up 0.19% at the 97.3660 level during the publication of this article.
While, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Monday. The SPY was down 0.13% at $624.54, while the QQQ declined 0.25% to $554.81, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46271577/trumps-big-beautiful-bill-slashes-solar-incentives-cathie-woods-ark-says-nuclear-may-now-be-cheapest-option-oklo-smr-ltbr-and-other-stocks-in-focus">Trump&#8217;s Big Beautiful Bill Slashes Solar Incentives — Cathie Wood&#8217;s Ark Says Nuclear May Now Be Cheapest Option: OKLO, SMR, LTBR And Other Stocks In Focus </a></li>
</ul>
Image via Shutterstock

News

As US Dollar Sinks, Top Economist Warns 10% Slide Could Spark New Inflation Spike

Barclays analyst Betty Jiang initiates coverage on EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight rating and announces Price Target of $65.

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On EQT with Overweight Rating, Announces Price Target of $65

White Mountains Insurance Group, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTM#NYSE">WTM</a>) announced today that it has entered into an agreement to acquire a majority stake in Distinguished Programs ("Distinguished" or the "Company"), an MGA and program administrator for specialty property &amp; casualty insurance. Following the acquisition, White Mountains will own a 51% controlling interest in Distinguished.
Distinguished is an MGA and program manager placing in excess of $550 million in premiums annually across a diversified portfolio of 12 specialty property and casualty programs such as commercial real estate, hotels &amp; restaurants, community associations, environmental &amp; construction professional, cyber, surety, executive lines, inland marine and fine arts &amp; collectibles. Distinguished is led by industry veterans Bill&nbsp;Malloy, Jason Rotman and Steve Sitterly.
Aquiline Capital Partners, the current controlling equityholder of Distinguished, will remain a significant minority equityholder going forward. Distinguished's current executive management team will continue to lead the business, and each will remain a significant equityholder.
&nbsp;
In the transaction, White Mountains will acquire approximately 50% of Distinguished's outstanding equity interests for $230 million. White Mountains currently owns approximately 1% of Distinguished's outstanding equity interests. The transaction is expected to close in the third quarter of 2025. The closing is subject to regulatory approvals and other customary closing conditions.&nbsp;

White Mountains Insurance Group To Acquire 51% Stake In Distinguished Programs, Will Acquire ~50% Of Distinguished's Outstanding Equity Interests For $230M

B of A Securities analyst Koji Ikeda maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $150 to $175.

DDOG

B of A Securities Maintains Buy on Datadog, Raises Price Target to $175

RGLD

Royal Gold shares are trading lower following an announcement that the company will acquire Sandstorm Gold for $3.5 billion,

SAND

Sandstorm Gold shares are trading higher after announcing that Royal Gold will acquire them for $3.5 billion.

B of A Securities analyst Michael Funk reinstates T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Neutral and announces $255 price target.

TMUS

B of A Securities Reinstates Neutral on T-Mobile US, Announces $255 Price Target

ENVX

Enovix shares are trading higher after the company reported better-than-expected Q2 financial results.

Barclays analyst Betty Jiang initiates coverage on CNX Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) with a Equal-Weight rating and announces Price Target of $33.

Barclays Initiates Coverage On CNX Resources with Equal-Weight Rating, Announces Price Target of $33

B of A Securities analyst Michael Funk reinstates Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Neutral and announces $45 price target.

B of A Securities Reinstates Neutral on Verizon Communications, Announces $45 Price Target

CRWV

CoreWeave shares are trading lower following an announcement to acquire Core Scientific in an all-stock deal.

B of A Securities analyst Michael Funk reinstates AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) with a Buy and announces $32 price target.

B of A Securities Reinstates Buy on AT&T, Announces $32 Price Target

Barclays analyst David Strauss initiates coverage on Voyager Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYG#NYSE">VOYG</a>) with a Equal-Weight rating and announces Price Target of $45.

VOYG

Barclays Initiates Coverage On Voyager Technologies with Equal-Weight Rating, Announces Price Target of $45

SHEL

Shell shares are trading lower after the company provided a Q2 update note stating expectations for adjusted earnings to be impacted by lower trade and optimisation.

STLA

Stellantis shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and cut its price target from $16.5 to $11.75.

B of A Securities analyst Ronald Epstein initiates coverage on Voyager Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYG#NYSE">VOYG</a>) with a Buy rating and announces Price Target of $50.

B of A Securities Initiates Coverage On Voyager Technologies with Buy Rating, Announces Price Target of $50

Leerink Partners analyst Faisal Khurshid assumes AbCellera Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) with a Outperform rating and announces Price Target of $5.

ABCL

Leerink Partners Assumes AbCellera Biologics at Outperform, Announces Price Target of $5

Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) ("Enovix"), a leader in advanced silicon battery technology, today announced the launch of the AI-1TM platform, its Artificial Intelligence ClassTM batteries for the next generation of mobile smartphones that require significantly higher total energy storage and power to perform AI functions locally. This revolutionary silicon-anode smartphone battery platform is protected by 190 Enovix architecture-specific patents that enable the use of 100% active silicon anodes. Last week, the company sampled its first 7,350 milliampere-hour (mAh) AI-1 batteries to a leading smartphone OEM for qualification in the first ever 100% silicon-anode battery smartphone launch.
With energy density exceeding 900 watt-hours per liter (Wh/L) and advanced capabilities for high discharge rate and long cycle life, Enovix believes AI-1 is the highest energy density battery commercially available in the market today. The company's patented battery architecture overcomes the notorious silicon anode swelling problems, enabling exceptional performance without compromising safety or longevity. The higher energy density provided by the AI-1 enables smartphone manufacturers to take full advantage of AI-enabled applications without requiring frequent charging cycles.&nbsp;&nbsp;
AI-1 Performance Highlights&#x2A;:
<ul>
<li>&gt;900 Wh/L energy density – highest commercially available</li>
<li>Fast charging at 3C rates – 20% charged in 5 minutes, 50% charged in 15 minutes</li>
<li>900+ cycles in standard smartphone usage based on initial unit testing</li>
<li>High discharge capability across wide temperature ranges – ideal for AI applications</li>
<li>Passed Enovix Safety Test Suite (ESTS): drop, tumble, thermal abuse, and external short circuit test</li>
</ul>

Enovix Launches AI-1 Silicon-Anode Battery Platform For Smartphones, Delivering Energy Density And Fast Charging For AI Applications

Management

Baxter Appoints Andrew Hider As CEO

Press Releases

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Earnings

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Comments

Spyre Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL